Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.
Journal: Advances in therapy
Published: June 01, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
Journal: Blood advances
Published: April 21, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.
Journal: Blood advances
Published: April 21, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.
Journal: Transplantation and cellular therapy
Published: February 12, 2026
Polymorphic IGLV6-57 AL amyloid fibrils and features of a shared folding pathway.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Polymorphic IGLV6-57 AL amyloid fibrils and features of a shared folding pathway.
Journal: Nature communications
Published: November 17, 2025
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists.
Journal: British journal of haematology
Published: November 01, 2025
Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.
Journal: British journal of haematology
Published: August 10, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Journal: American journal of hematology
Published: July 30, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Journal: Blood cancer journal
Published: June 30, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.
Journal: Transplantation and cellular therapy
Published: May 05, 2025
Last Updated: 09/26/2026